当前位置:主页 > 医学论文 > 肿瘤论文 >

ICE治疗84例复发难治性弥漫大B细胞淋巴瘤的疗效及预后分析

发布时间:2019-07-18 16:58
【摘要】:目的·研究ICE(异环磷酰胺、卡铂、依托泊苷)方案治疗复发难治性弥漫大B细胞淋巴瘤(DLBCL)患者的有效性及相关预后因素。方法·回顾性分析2004年7月—2016年6月收治的84例初发进展期及复发难治性DLBCL患者的临床资料,给予ICE方案化疗,采用Kaplan-Meier方法计算总生存期,并采用Cox回归方法进行多因素分析。结果·84例患者中26例达完全缓解,11例达部分缓解,客观缓解率为44.0%;获得缓解所需的化疗疗程的中位数为3个(1~6个)。1年总体生存率为49.5%,2年总体生存率为30.0%,中位生存期为12.2个月。单因素分析显示早期复发或进展(P=0.041)、IPI中高危/高危(P=0.024)及NCCN-IPI中高危/高危(P=0.002)是影响患者生存的不良因素,化疗后缓解与延长患者生存显著相关(P=0.000);多因素分析提示NCCN-IPI中高危/高危为影响患者生存的独立危险因素,化疗后缓解为延长患者生存的独立预后指标。结论·ICE方案可作为复发难治性DLBCL患者的有效挽救性治疗方案。
[Abstract]:Objective To study the efficacy and relevant prognostic factors in the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL) with ICE (heterocyclophosphamide, carboplatin, and depending on the poises) regimen. Methods The clinical data of 84 patients with advanced and refractory DLBCL from July 2004 to June 2016 were analyzed retrospectively. The overall survival was calculated by using the Kaplan-Meier method and the multi-factor analysis was performed using the Cox regression method. Results: Of the 84 patients,26 of the 84 patients had complete remission,11 had a partial response, the objective response rate was 44.0%, and the median of the chemotherapy courses required for remission was 3 (1 to 6). The overall survival rate was 49.5%, the overall survival rate of 2 years was 30.0%, and the median survival time was 12.2 months. Single factor analysis showed that early recurrence or progression (P = 0.041), high risk/ high risk in IPI (P = 0.024) and high risk/ high risk (P = 0.002) in NCCN-IPI were the adverse factors that affected the survival of patients. The multi-factor analysis indicates that the high-risk/ high-risk in the NCCN-IPI is an independent risk factor affecting the survival of the patient, and the independent prognostic indicator for prolonging the survival of the patient is relieved after the chemotherapy. Conclusion The ICE regimen can be used as an effective salvage therapy in patients with refractory DLBCL.
【作者单位】: 上海交通大学医学院附属瑞金医院血液科联合病房(徐汇区中心医院);上海交通大学医学院附属瑞金医院血液科;上海交通大学医学院附属瑞金医院血液科联合病房(北站医院血液科);
【基金】:国家自然科学基金(81325003,81520108003,81670716,81201863) 上海市杰出青年医学人才培养资助计划 上海市教育委员会高峰高原学科建设计划(20152206,20152208) 上海市科学技术委员会项目(14430723400,14140903100,16JC1405800) 静安区卫生科研课题(2016MS11) 徐汇区中心医院院级科研课题(2014XHYY-04) 上海交通大学SMC-晨星青年学者奖励计划~~
【分类号】:R733.1

【参考文献】

相关期刊论文 前3条

1 朱贵华;李秀梅;庄万传;江亚军;何耀;柴星星;;沙利度胺联合ICE方案治疗复发性难治性非霍奇金淋巴瘤[J];现代肿瘤医学;2014年07期

2 郝杰;李雪莲;李良群;关爽;王黎;;MINE与ICE方案治疗复发难治性淋巴瘤的疗效比较[J];实用癌症杂志;2012年01期

3 孙中义;易平勇;刘晰宇;周芳;欧阳周;贺军侨;黄利军;姚远;;ICE方案和GemOX方案治疗复发或难治性弥漫大B细胞淋巴瘤的临床观察[J];中国医师杂志;2013年02期

【共引文献】

相关期刊论文 前10条

1 郑重;孙渊渊;夏O,

本文编号:2515983


资料下载
论文发表

本文链接:https://www.wllwen.com/yixuelunwen/zlx/2515983.html


Copyright(c)文论论文网All Rights Reserved | 网站地图 |

版权申明:资料由用户90f59***提供,本站仅收录摘要或目录,作者需要删除请E-mail邮箱bigeng88@qq.com